CClinicalTrials.gg
CompletedNCT03408366Updated Aug 2, 2022

A Study Assessing Circulation Around Surgical Incisions at the Time of Laparotomy Closure

An interventional study of Laparotomy and ICG in Laparotomy, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 8 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-02.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This study is being done to find out if Spectrum Near-Infrared (NIR) imaging with Indocyanine Green (ICG) dye can help measure blood flow around an incision before and after the surgeon closes the incision with staples or sutures.

The Spectrum NIR imaging system uses a handheld camera that produces a special type of light that can help surgeons see things during surgery that are difficult to see with the naked eye, for example, cancer tissue versus healthy tissue. Spectrum NIR imaging has been approved by the Food and Drug Administration (FDA) as a tool that is widely used during surgery.

ICG dye is a sterile solution that can be seen with Spectrum NIR imaging. This dye, used with Spectrum NIR imaging, allows surgeons to see blood flow to parts of the body during and after surgery. Making sure that there is enough blood flow to the surgical site helps to promote a less complicated recovery.

02

Conditions studied

  • Laparotomy

Browse trials for

Keywords

  • Laparotomy
  • Surgical Incisions
  • Wound Perfusion
  • 17-650
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Criteria for Eligibility Prior to Surgery

Inclusion Criteria:

  • Woman undergoing a laparotomy procedure via a vertical midline incision for any indication with the Gynecology Service at MSK
  • Age ≥18 years

Exclusion Criteria:

  • Women with hepatic dysfunction as evidenced by elevated transaminases
  • Women with a history of cirrhosis or other chronic liver disease
  • Women with an allergy to iodine
  • Women undergoing laparoscopic or minimally invasive surgery

Criteria for Eligibility Post-Surgery

Inclusion Criteria:

  • Woman undergoing a laparotomy procedure via a vertical midline incision for any indication with the Gynecology Service at MSK
  • Age ≥18 years

Subject Exclusion Criteria:

  • Women with laparotomy incisions unable to be closed primarily due to tissue or fascial damage
  • Women with transverse laparotomy incisions
  • Women with laparotomy incisions left open due to a case classification as "contaminated" or "dirty"
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Women having a Laparotomy

    The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.

    Procedure: Laparotomy · Other: ICG · Other: Spectrum NIR imaging system

Interventions

  • ProcedureLaparotomy

    Laparotomy via vertical midline incision and after the planned surgical procedure is complete.

  • OtherICG

    ICG will be injected intravenously ICG is a fluorescent iodide dye.

  • OtherSpectrum NIR imaging system

    The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.

05

What researchers measure

Primary outcomes

  1. percentage of cases with successful perfusion measurements

    Feasibility will be determined by the percentage of cases with successful perfusion measurements.

    Time frame: 1 year

06

Study locations

8 sites
  • Memoral Sloan Kettering Basking Ridge (Consent only)
    Basking Ridge, New Jersey 07920, United States
  • Memoral Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen (Consent only )
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Commack (Consent only)
    Commack, New York 11725, United States
  • Memoral Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Rockville Centre (Consent only)
    Rockville Centre, New York 11570, United States
  • Memorial Sloan Kettering Nassau (Consent only)
    Uniondale, New York 11553, United States
07

References and documents

08

Registry details

Key details

Study ID
NCT03408366
Lead sponsor
Memorial Sloan Kettering Cancer Center
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Jan 15, 2018
Primary completion
Aug 1, 2022
Completion
Aug 1, 2022
Last update
Aug 2, 2022

Study contacts

Nadeem Abu-Rustum, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion